Cabergoline: A review of its use in the treatment of Parkinson's disease

Drugs

Volumn 64, Issue 18, 2004, Pages 2125-2141

  Curran, Monique P ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; LEVODOPA; PERGOLIDE; SEROTONIN RECEPTOR;

ADULT; AGED; AKINESIA; CENTRAL NERVOUS SYSTEM DISEASE; CHOREA; CLINICAL TRIAL; CONFUSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSKINESIA; DYSPEPSIA; DYSTONIA; GASTRITIS; HALLUCINATION; HEART MUSCLE FIBROSIS; HUMAN; HYPERKINESIA; INCIDENCE; INFLAMMATORY DISEASE; LUNG FIBROSIS; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERICARDIAL EFFUSION; PERICARDITIS; PERIPHERAL EDEMA; PLEURA EFFUSION; PLEURISY; RECEPTOR AFFINITY; RETROPERITONEAL FIBROSIS; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

ANTIPARKINSON AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; HUMANS; PARKINSON DISEASE;

ANIMALIA; PARKINSONIA;

EID: 4644282982     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464180-00015     Document Type: Review

References (93)

1. Ahlskog JE. Parkinson's disease: medical and surgical treatment. Neurol Clin 2001; 19 (3): 579-605
2. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56 (1): 33-9
3. Lam YW. Clinical pharmacology of dopamine agonists. Pharmacotherapy 2000 Jan; 20 (1 Pt 2): 17S-25S
4. Clarke CE, Gunman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002 Nov 30; 360 (9347): 1767-9
5. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56 (11 Suppl. 5): S1-S88
6. Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline: rationale for use in Parkinson's disease. Drugs 1998; 55 Suppl. 1: 10-6
7. Wiseman LR, Fitton A. Cabergoline: a review of its efficacy in the treatment of Parkinson's disease. CNS Drugs 1999 Dec; 12 (6): 485-97
8. 1 receptor agonists: the way forward for the treatment of Parkinson's disease? CNS Drugs 1999; 11 (2): 83-91
9. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001; 90 (2-3): 231-59
10. 3 receptors: relevance for the drug treatment of Parkinson's disease. CNS Drugs 1999; 12(5): 391-402
11. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I: a multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002 Nov; 303 (2): 791-804
12. 2-adrenoceptor. J Pharmacol Exp Ther 2002 Nov; 303 (2): 805-14
13. Gerlach M, Double K, Reichmann H, et al. Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease. J Neural Transm Suppl 2003; (65): 167-83
14. 2, receptor subtypes. J Pharmacol Exp Ther 2002 Nov; 303 (2): 815-22
15. Bergström M, Hartvig P, Nava C, et al. Effects of cabergoline on striatal dopamine receptor binding and dopamine synthesis: in vivo study in monkey with positron emission tomography [abstract no. 15-11]. Proceedings of the 18th Annual Meeting of the European Neuroscience Association; 1995 Sep 3-7; Amsterdam, 192
16. Arai N, Isaji M, Miyata H, et al. Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. J Neural Transm - Park Dis Dement Sect 1995; 10 (1): 55-62
17. Nomoto M, Kita S, Iwata SI, et al. Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets. Pharmacol Biochem Behav 1998; 59 (3): 717-21
18. Belanger N, Gregoire L, Tahar AH, et al. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 2003 Dec; 18 (12): 1436-41
19. Hadj Tahar A, Gregoire L, Bangassoro E, et al. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 2000 Jul 31; 23 (4): 195-202
20. 2 agonist, on reserpine-treated rodents. Biol Pharm Bull 1996; 19 (11): 1499-502
21. Katayama S. Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy. Eur Neurol 2001; 46 Suppl. 1: 11-7
22. Lombardi G, Varsaldi F, Miglio G, et al. Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress. Eur J Pharmacol 2002 Dec 20; 457 (2-3): 95-8
23. Yoshida T, Tanaka M, Suzuki Y, et al. Antioxidant properties of cabergoline: inhibition of brain auto-oxidation and superoxide anion production of microglial cells in rats. Neurosci Lett 2002 Sep 13; 330(1): 1-4
24. Ohta K, Kuno S, Mizuta I, et al. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Life Sci 2003 Jun 20; 73 (5): 617-26
25. Ohta K, Fujinami A, Kuno S, et al. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 2004; 71: 162-8
26. Finotti N, Castagna L, Moretti A, et al. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res 2000 Oct; 42 (4): 287-91
27. Yoshioka M, Tanaka K, Miyazaki I, et al. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci Res 2002 Jul; 43 (3): 259-67
28. Poewe W, Hogl B. Parkinson's disease and sleep. Curr Opin Neurol 2000; 13 (4): 423-6
29. Stacy M. Sleep disorders in Parkinson's disease: epidemiology and management. Drugs Aging 2002; 19 (10): 733-9
30. Zesiewicz TA, Hauser RA. Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known? CNS Drugs 2003; 17 (8): 593-600
31. Chaudhuri KR, Bhattacharya FK. The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disturbances: a parallel study with controlled-release levodopa. Eur J Neurol 1999; 6 Suppl. 5: S11-5
32. Hogl B, Rothdach A, Wetter TC, et al. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 2003 Oct; 28 (10): 1866-70
33. Chaudhuri KR, Agapito C, Porter MC, et al. Cabergoline, a long-acting dopamine agonist, overcomes levodopa refractory nocturnal disabilities in Parkinson's disease. Neurology 1999 Apr 12; 52 Suppl. 2: 263
34. Ghatani T, Agapito C, Bhattacharya KF, et al. Comparative audit of pergolide and cabergoline therapy in the treatment of nocturnal 'off' periods causing sleep disruption in Parkinson's disease. Eur J Neurol 2001; 8 Suppl. 1:8-11
35. Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet 2003; 42 (7): 633-45
36. Lera G, Vaamonde J, Rodriguez M, et al. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993 Dec; 43: 2587-90
37. Persiani S, Rocchetti M, Pacciarini MA, et al. The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. Biopharm Drug Dispos 1996; 17 (5): 443-55
38. Rahimy MK, Bolyard KB, Knuth DW, et al. Single- and multiple-dose pharmacokinetics evaluation of cabergoline in healthy young and elderly volunteers [abstract no P-TU-225]. Parkinsonism Relat Disord 2001; 7 Suppl. 1: S67
39. Del Dotto P, Colzi A, Musatti E, et al. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease. Clin Neuropharmacol 1997 Oct; 20 (5): 455-65
40. Dostert P, Strolin Benedetti M, Persiani S, et al. Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. J Neural Transm Suppl 1995; 45: 247-57
41. Nomura T, Zhang J, Nakatsuka A, et al. Pharmacokinetic study on the interaction between cabergoline and clarithromycin in healthy volunteers [abstract no. ICI354]. J Pharmacol Sci 2003; 91 Suppl. 1: 74P
42. Mutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996 Apr; 46: 1062-5
43. Musch B, Bonura L, Investigator Study Group. Cabergoline once a day as adjunctive therapy to levodopa in Parkinson's disease [abstract no. 3 plus poster]. Mov Disord 2000; 15 Suppl. 3: 121
44. Destee A, Schneider E, Gershanik O, et al. Efficacy and tolerability of cabergoline compared to bromocriptine in patients suffering from levodopa associated motor complications (not on treatment with DA-agents) [abstract no. SS26]. Mov Disord 1996; 11 Suppl. 1: 269
45. Schneider E, Gershanik O, Dom R, et al. Efficacy and tolerability of cabergoline compared to bromocriptine in patients suffering from levodopa associated motor complications (on treatment with DA-agents) [abstract no. SS27]. Mov Disord 1996; 11 Suppl. 1:269
46. Yanagisawa N, Kowa H, Mizuno Y, et al. The clinical evaluation of CG-101 (cabergoline) in Parkinson's disease with combined use of L-DOPA: a multi-centered double-blind comparative study vs. bromocriptine mesilate [in Japanese]. Rinsho Iyaku 1996; 12 (17): 3757-98
47. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. Drugs 1998; 55 Suppl. 1: 23-30
48. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004; 18 (11): 733-46
49. Lieberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993 Oct; 43: 1981-4
50. Steiger MJ, El-Debas T, Anderson T, et al. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996 Jan; 243 (1): 68-72
51. Ahlskog JE, Wright KF, Muenter MD, et al. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996 Jun; 19 (3): 202-12
52. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996 Sep; 47: 785-8
53. Ulm G, Schuler P. Cabergoline versus pergolide: a video-blinded, randomised multicenter cross-over study [in German]. Aktuel Neurol 1999; 26 (8): 360-5
54. Clarke CE, Deane KD. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2003; 3
55. Clarke CE, Deane KH. Cabergoline for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2003; 3
56. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997 Feb; 48: 363-8
57. Smala AM, Siebert U, Oertel WH, et al. Reply: cabergoline versus levodopa therapy [letter]. Mov Disord 2004; 19 (6): 734-5
58. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001; 19 (10): 1013-38
59. Smala AM, Spottke EA, Machat O, et al. Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord 2003 Aug; 18 (8): 898-905
60. Lindgren P, Jonsson B, DuChane J. The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden. Eur J Health Econ 2003; 4 (1): 37-42
61. Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs 1998; 55 Suppl. 1: 17-22
62. Pharmacia. Cabaser tablets 1 mg [UK prescribing information]. Pharmacia: Milton Keynes, 2003
63. Forbes A, Brechany U, Stegie F, et al. Use and tolerability of cabergoline in young and older people with Parkinson's disease: a multi-center observational study. J Appl Res 2003; 3 (4): 356-62
64. Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease [letter]. Clin Neuropharmacol 2003; 26 (3): 109-11
65. Fibrotic reactions with pergolide and other ergot-derived dopamine receptor agonists. Curr Probl Pharmacovigilance 2002 Apr; 28: 3
66. Frank W, Moritz R, Becke B, et al. Low dose cabergoline induced interstitial pneumonitis. Eur Respir J 1999 Oct; 14 (4): 968-70
67. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992 Feb; 5 (2): 263-5
68. Dhawan V, Stegie F, Metcalf P, et al. What is the risk of cardiopulmonary fibrosis with cabergoline use in Parkinson's disease: an observational study of 224 cases. Proceedings of the Association of British Neurologists; 2004 Apr 14-16; London
69. Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999; 74 (4): 371-5
70. Ferreira JJ, Pona N, Costa J, et al. Somnolence as an adverse drug reaction of antiparkinsonian drugs: a meta-analysis of published randomised placebo-controlled trials [abstract no. P659). Mov Disord 2000; 15 Suppl. 3: 128
71. Pal S, Bhattacharya K, Agapito C, et al. A comparative study of daytime sleepiness within Parkinson's disease patients treated with cabergoline, pramipexole and levodopa (abstract no. P593]. Mov Disord 2000; 15 Suppl. 3: 110-1
72. Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003 Jun; 18 (6): 659-67
73. Pal S, Bhattacharya KF, Agapito C, et al. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm 2001; 108 (1): 71-8
74. Del Dotto P, Gambaccini G, Caneparo D, et al. Bedtime cabergoline in Parkinson's disease patients with excessive daytime sleepiness induced by dopamine agonists. Neurol Sci 2003 Oct; 24 (3): 170-1
75. de Rijk MC, Tzourio C, Breteler MMB, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 1997 Jan; 62: 10-5
76. Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson's disease on health status, health expenditures, and productivity: estimates from the National Medical Expenditure Survey. Pharmacoeconomics 1997 Oct; 12 (4): 486-98
77. Conley SC, Kirchner JT. Medical and surgical treatment of Parkinson's disease: strategies to slow symptom progression and improve quality of life. Postgrad Med 1999 Aug; 106 (2): 41-52
78. Martignoni F, Riboldazzi G, Calandrella D, et al. Motor complications of Parkinson's disease. Neurol Sci 2003; 24 Suppl. 1: S27-9
79. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61
80. Whone A, Watts R, Stoessl J. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101
81. Schapira AHV, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths and misconceptions. JAMA 2004; 291: 358-64
82. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2002; 58 (1): 11-7
83. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16 (3): 448-58
84. Obeso JA, Rodriguez-Oroz MC, Chana P, et al. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000; 55 (11 Suppl. 4): S13-23
85. Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 1999; 14 (6): 911-3
86. Woolen GF. Agonists vs levodopa in PD: the thrilla of whitha. Neurology 2003; 60 (3): 360-2
87. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003; 60 (3): 381-9
88. Albin RL, Frey KA. Initial agonist treatment of Parkinson disease: a critique. Neurology 2003; 60 (3): 390-4
89. Wheatley K, Clarke CE, Ives N. Cabergoline vs. levodopa monotherapy [letter]. Mov Disord 2002; 19 (6): 733-4
90. Marras C. Re: cabergoline versus levodopa monotherapy: a decision analysis [letter]. Mov Disord 2004; 19 (6): 736
91. Chaudhuri KR, Pal S, Brefel-Courbon C. 'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect? Drug Saf 2002; 25 (7): 473-83
92. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002 Jun 22; 324 (7352): 1483-7
93. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52 (9): 1908-10